Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...
Drug compounders have filed a lawsuit against the FDA for removing Novo Nordisk's Wegovy and Ozempic from its shortage list. This decision restricts compounders from selling cheaper versions, despite ...
Makers of copycat versions of Novo Nordisk's (NVO) weight-loss drug semaglutide, also known as Ozempic and Wegovy, are suing ...
On Friday, the US Food and Drug Administration announced drugs Wegovy and Ozempic by Novo Nordisk are no longer in shortage.
KBW and UBS raised price targets on shares of Warren Buffett's Berkshire Hathaway after the conglomerate reported blowout fourth-quarter earnings on Saturday. Hims shares have roughly doubled since ...
Hims & Hers (HIMS) stock tumbled 20% post-market after the company released its Q4 earnings report and 2025 guidance amid a ...
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...
Compounders have filed a lawsuit against the FDA challenging its decision to remove Novo Nordisk's Wegovy and Ozempic from the shortage list. The lawsuit claims the FDA's actions are arbitrary, ...
Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's ...
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...
The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk's (NYSE:NVO) was ...
Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling ...